Zogenix gets an unwelcome distraction from Fintepla
Spending $250m on Modis gives Zogenix a new rare disease niche, but the timing and the target both look odd.
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
The Sarepta fairy tale takes a worrying turn
A complete response letter for Sarepta’s follow-on Duchenne therapy is a big blow for the company, but in hindsight was the FDA’s decision actually that surprising?
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Novel drug approvals head for a down year
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
Cannabis, M&A and data spur strong gains among small and midcaps
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
PPMD 2019 – Pfizer’s Duchenne gene therapy halt is good news for Sarepta
Worries over toxicity with Pfizer's PF-06939926 halts trial dosing and could leave the way clear for its DMD rival Sarepta.
Array-size deals don’t come around too often
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Vertex’s second transformation: Duchenne time
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.